AKT Health at BioAsia 2025: Showcasing Innovation in Digital Health

The 22nd edition of BioAsia 2025 was a testament to the transformative power of innovation and collaboration in life sciences and healthcare. With the theme “Catalysts of Change – Expanding Global Healthcare Frontiers, Transforming Healthcare with Innovation, Collaboration, and Progress,” the event brought together global industry leaders, innovators, and policymakers. Inaugurated by A Revanth Reddy, CM of Telangana, Dr. Jeannette Young, Governor of Queensland, and D Sridhar Babu, Minister for Industries and Commerce, Government of Telangana, BioAsia 2025 set the stage for thought-provoking discussions and groundbreaking solutions.

Amidst this global gathering, AKT Health made a significant impact with two dedicated booths: Booth P4 in the Startup Zone, where Impakt Health unveiled its transformative digital health solutions, and Booth 34, where AKT Health showcased its cutting-edge Clinical, Medical, Commercial, Outcome services, along with Certara’s industry-leading drug development technologies.

Driving the Future of Digital Health with Impakt Health

Positioned at Booth P4 in the Startup Zone, Impakt Health demonstrated its commitment to revolutionizing patient care through digital health solutions, AI-driven interventions, and decentralized clinical trials (DCTs). In a healthcare landscape where remote patient monitoring and personalized treatment are becoming the norm, Impakt Health bridges the gap between technology and real-world patient needs.

From AI-powered behavioral interventions to loMT & blockchain-based architecture, Impakt Health's solutions are designed to enhance patient adherence, improve clinical outcomes, and empower both providers and patients with real-time health insights. The Impakt Life suite of smart devices, including intelligent ECG recorders, infrared thermometers, blood pressure monitors, pulse oximeters, and the Smart Ring for sleep and health tracking, captivated visitors with its potential to transform remote healthcare.

Dr. Mitsuhiro Marumoto, Chief Medical Officer of AKT Health, emphasized the role of strategic partnerships in advancing healthcare innovation:

Certara: Powering Drug Development and Regulatory Science at Booth 34

Alongside the innovations in digital health, AKT Health also proudly showcased Certara’s industry-leading solutions in drug discovery, pharmacokinetic/pharmacodynamic (PK/PD) data analysis, regulatory submissions, and medical writing. As a global powerhouse in biosimulation and regulatory sciences, Certara’s solutions enable pharmaceutical companies, CROs, and research institutions to accelerate drug development, ensure regulatory compliance, and improve patient safety through predictive modeling and advanced data analytics.

Visitors to Booth 34 were introduced to Certara’s best-in-class technologies:

• Phoenix WinNonlin, NLME & IVIVC: Industry-standard solutions for advanced PK/PD modeling and simulation, critical for accelerating drug development and optimizing dosing strategies.

• Simcyp Discovery & Simcyp Services: A game-changer in physiologically-based pharmacokinetic (PBPK) modeling, enabling researchers to predict drug interactions and enhance drug safety.

• Global Submit, PK Submit & Pinnacle 21: Cutting-edge regulatory submission tools that streamline compliance with global health authorities, reducing time-to-market for new therapies.

And more....

Reflecting on the success of BioAsia 2025, Rashmi Gurnani, CEO of AKT Health, shared her thoughts on the impact of the event

With AKT Health’s deep expertise in life sciences and Certara’s groundbreaking solutions, the event provided a unique opportunity to engage with pharmaceutical companies, regulatory professionals, and researchers looking to advance drug development and market access strategies.

At the core of AKT Health’s presence at BioAsia 2025 was its unwavering mission to drive technological innovation in healthcare. Through decentralized clinical trials (DCTs), AI-powered analytics, and blockchain-driven healthcare solutions, AKT Health is shaping the future of clinical research and patient-centric care.

With a dual presence at BioAsia 2025, AKT Health successfully demonstrated how technology, innovation, and collaboration can unlock new frontiers in healthcare and life sciences.

As the global healthcare industry accelerates its adoption of AI, biosimulation, and decentralized models, AKT Health stands at the forefront, bridging the gap between cutting-edge technology and real-world healthcare needs.

With BioAsia 2025 as a catalyst, AKT Health continues to pioneer AI-powered solutions that transform clinical trials, patient engagement, and regulatory strategies. With a strong presence across India, Japan, the US, Switzerland, and the Middle East, we remain dedicated to integrating technology with healthcare to create more accessible, data-driven, and patient-focused solutions.

Learn more about how AKT Health is shaping the future of digital healthcare at www.akthealth.com